CDXC Earnings Prediction
The chart below shows how CDXC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CDXC sees a -4.92% change in stock price 10 days leading up to the earnings, and a +21.89% change 10 days following the report. On the earnings day itself, the stock moves by +1.98%. This data can give you a slight idea of what to expect for the next quarter's release.
CDXC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
CDXC Earnings Analysis
Chromadex Corp Corporation (CDXC.O) Earnings Conference Call
Positive
Earnings Surprise Achievement: ChromaDex Corporation beats earnings expectations with reported EPS of $0.09, exceeding expectations of $0.02.
Record Revenue Achievement: In Q4 2024, ChromaDex achieved record revenues of $29.1 million, a 37% increase year-over-year.
Net Revenue Growth: For the full year, net revenues reached $99.6 million, reflecting a 19% growth year-over-year.
Positive Cash Flow Generation: The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt.
E-commerce Sales Surge: E-commerce channel saw robust organic growth with net sales of $17.3 million, a 30% increase year-over-year.
Niagen Sales Surge: Food grade and pharmaceutical-grade Niagen ingredient business had net sales of $5.3 million, a 96% increase year-over-year.
Improved Gross Margins: Gross margins improved to 61.8%, reflecting continued operational efficiency and cost management.
Marketing Efficiency Improvement: Selling and marketing expenses decreased as a percentage of net sales, indicating improved efficiency in marketing investments.
Administrative Expense Reduction: General and administrative expenses decreased by $4.4 million year-over-year, contributing to improved profitability.
Operating Income Turnaround: Operating income in Q4 2024 was $7.1 million, a significant turnaround from a $200,000 operating loss in Q4 2023.
Future Growth Potential: ChromaDex is well-positioned for future growth with a strong financial position and plans for continued investment in innovation.
Negative
Supply Chain Delays Impact Launch: The company faced supply chain issues that delayed the availability of pharmaceutical-grade Niagen by 2 to 3 months, impacting the launch of the Niagen Plus product line.
Industry Concerns Impacting Growth: Despite a strong financial performance, the company highlighted concerns about misleading practices in the industry, indicating a competitive environment that could affect future growth.
Rising Administrative Expenses: General and administrative expenses are expected to increase by approximately $5 million to $6 million in 2025, which could impact profitability.
NO-PARK Study Uncertainty: The company is still awaiting results from the NO-PARK study for Parkinson's disease, indicating uncertainty in the timeline for potential new product developments.
Regulatory Action Needed: The company mentioned the need for more regulatory action from the FDA and FTC to prevent misleading practices in the market, suggesting ongoing challenges in maintaining product integrity.
CDXC FAQs
How does CDXC typically perform around its earnings report dates?
Is Chromadex Corp (CDXC) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CDXC Earning Call Sentiment
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript
CDXC.O
52.68%Positive
The company reported record revenue growth and strong e-commerce performance, which are positive indicators. Despite some supply chain issues, management remains optimistic about growth, especially with the Niagen IV expansion and potential partnerships. The Q&A revealed uncertainties in the NO PARK study and NAD+ testing, but these were not major concerns. Overall, the positive revenue outlook and strong product development outweigh the minor uncertainties, suggesting a positive stock price movement in the near term.
